Work in our lab focuses on immune regulation in hematopoietic stem cell transplantation (HSCT) and on developing novel platforms for cellular therapies. HSCT can cure high-risk malignancies and other diseases of the blood and bone marrow, yet success is limited as many patients develop graft-versus-host disease (GVHD), a debilitating and potentially fatal complication of HSCT.
We aim to elucidate the biological mechanisms underlying immune tolerance in HSCT, develop approaches to enhance regulatory immune cells for GVHD prevention and design improved cancer targeting cellular therapies for safer and more effective treatment. Our goal is to use a bench-to-bedside approach to engineer viable cell-based therapeutics for preventative and curative treatments, thereby making HSCT and cellular therapies safer ways to cure cancer and other blood diseases, giving survivors long, healthy lives.
Are you interested in joining our team?
Learn more about opportunities in our lab.
Left to right: Maria Mai, Emily Landy, Nathan Schedler, Melissa Mavers, Joanne Sung, Sam Signorelli, Kelsey Busken.
Work in the Mavers lab has received support from:
Hyundai Hope on Wheels
Cancer Research Foundation
National Institutes of Health (NHLBI)
Pedal The Cause
Siteman Cancer Center
News
Mavers receives the Hyundai Hope on Wheels Hope Scholar Award
Arnav completes the Summer Public Health Scholars Program
